Movatterモバイル変換

[0]ホーム
URL:

Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature Medicine
  • Comment
  • Published:

Psychedelic therapy: a roadmap for wider acceptance and utilization

Nature Medicinevolume 27, pages1669–1671 (2021)Cite this article

Subjects

Psychedelics have shown great promise in treating mental-health conditions, but their use is severely limited by legal obstacles, which could be overcome.

This is a preview of subscription content,access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

9,800 Yen / 30 days

cancel any time

Subscription info for Japanese customers

We have a dedicated website for our Japanese customers. Please go tonatureasia.com to subscribe to this journal.

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

￥ 4,980

Prices may be subject to local taxes which are calculated during checkout

References

  1. Marks, M.N. Y. Univ. J. Legis. Public Policy21, 69–140 (2018).

    Google Scholar 

  2. Davis, A. K. et al.JAMA Psychiatry78, 481–489 (2021).

    Article  Google Scholar 

  3. Mithoefer, M. C. et al.Psychopharmacol.236, 2735–2745 (2019).

    Article CAS  Google Scholar 

  4. Griffiths, R. R., Johnson, M. W. & Carducci, M. A.J. Psychopharmacol.30, 1181–1197 (2016).

    Article CAS  Google Scholar 

  5. Johnson, M. W., Griffiths, R. R. & Hendricks, P. S.Neuropharmacol.142, 143–166 (2018).

    Article CAS  Google Scholar 

  6. De Veen, B. T. H.Expert Rev. Neurother.17, 203–212 (2016).

    Article  Google Scholar 

  7. van Amsterdam, J., Opperhuizen, A. & van den Brink, W.Regul. Toxicol. Pharmacol.59, 423–429 (2011).

    Article  Google Scholar 

  8. Brooks, M.Medscapehttps://www.medscape.com/viewarticle/921789 (2019).

  9. Marks, M. M.Adm. Law Rev.72, 649–718 (2020).

    Google Scholar 

  10. National Institutes of Health.https://grants.nih.gov/grants/policy/nihgps/html5/section_4/4.2.7_promotion_or_legalization_of_controlled_substances.htm (2021).

  11. McCall, B.Nat. Med.https://www.nature.com/articles/d41591-020-00001-5 (2020).

  12. Michaels, T. I., Purdon, J., Collins, A. & Williams, M. T.BMC Psychiatry18, 245–259 (2018).

    Article  Google Scholar 

  13. Hickey, K.J.Congress. Res. Serv.https://crsreports.congress.gov/product/details?prodcode=R46525 (2020).

  14. US Patent 10,947,257 (filed 9 October 2018).

  15. Angermayer, C.LinkedInhttps://www.linkedin.com/pulse/open-letter-tim-ferriss-value-patents-psychedelic-angermayer/ (2021).

  16. Love, S.Motherboardhttps://www.vice.com/en/article/m7amw4/is-it-possible-to-create-an-ethical-psychedelics-company (2021).

  17. Lidsky, L.STAT First Opinionhttps://www.statnews.com/2019/07/23/patent-reform-protect-access-lifesaving-drugs/ (2019).

  18. Love, S.Motherboardhttps://www.vice.com/en/article/g5gdzy/can-lsd-treat-food-allergies-we-dont-know-but-its-already-been-patented (2021).

  19. Richert, L.Psychology Todayhttps://www.psychologytoday.com/us/blog/hygieias-workshop/202107/the-complicated-patenting-our-psychedelic-future (2021).

  20. Schreck, M.MAPS Bulletin21, 26–28 (2011).

    Google Scholar 

  21. Marks, M.Gizmodohttps://gizmodo.com/inside-the-fight-to-legalize-psilocybin-therapy-in-oreg-1845450885 (2020).

  22. Agin-Liebes, G. I. et al.J. Psychopharmacol.34, 155–166 (2020).

    Article  Google Scholar 

  23. Acker, L.The Oregonianhttps://www.oregonlive.com/pacific-northwest-news/2021/03/governor-appoints-board-to-oversee-oregons-new-psychedelic-mushroom-program.html (2021).

Download references

Acknowledgements

We are grateful for the support of the Saisei Foundation and thank E. Wright Clayton and R. Sachs for helpful comments on an earlier draft of this article.

Author information

Authors and Affiliations

  1. Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Cambridge, MA, USA

    Mason Marks & I. Glenn Cohen

  2. University of New Hampshire Franklin Pierce School of Law, Concord, NH, USA

    Mason Marks

  3. Harvard Law School, Cambridge, MA, USA

    I. Glenn Cohen

Authors
  1. Mason Marks
  2. I. Glenn Cohen

Contributions

M.M. and I.G.C. drafted the manuscript.

Corresponding author

Correspondence toMason Marks.

Ethics declarations

Competing interests

I.G.C. and M.M.’s work was supported by the Project on Psychedelics Law and Regulation (POPLAR), which itself receives funding from the Saisei Foundation, a non-profit organization based in Austin, Texas. M.M. is a governor-appointed member of the Oregon Psilocybin Advisory Board and chairs its licensing subcommittee.

Rights and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marks, M., Cohen, I.G. Psychedelic therapy: a roadmap for wider acceptance and utilization.Nat Med27, 1669–1671 (2021). https://doi.org/10.1038/s41591-021-01530-3

Download citation

This article is cited by

Access through your institution
Buy or subscribe

Associated content

Nature Outlook

Psychedelic medicine

Advertisement

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for theNature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly.Sign up for Nature Briefing: Translational Research
[8]ページ先頭
©2009-2026 Movatter.jp